Pre-order Enquiry
Request Free Sample
Global Hemophilia Drugs Market Research Report 2021
SKU ID : QYR-17221482 | Publishing Date : 20-Jan-2021 | No. of pages : 124
Detailed TOC of Global Hemophilia Drugs Market Research Report 2021
1 Hemophilia Drugs Market Overview1.1 Product Overview and Scope of Hemophilia Drugs
1.2 Hemophilia Drugs Segment by Type
1.2.1 Global Hemophilia Drugs Sales Growth Rate Comparison by Type (2021-2027)
1.2.2 Hemophilia A
1.2.3 Inhibitors
1.2.4 Hemophilia B
1.2.5 Von Willebrand Disease
1.3 Hemophilia Drugs Segment by Application
1.3.1 Hemophilia Drugs Sales Comparison by Application: (2021-2027)
1.3.2 Recombinant Therapies
1.3.3 Plasma-Derived Therapies
1.4 Global Hemophilia Drugs Market Size Estimates and Forecasts
1.4.1 Global Hemophilia Drugs Revenue 2016-2027
1.4.2 Global Hemophilia Drugs Sales 2016-2027
1.4.3 Hemophilia Drugs Market Size by Region: 2016 Versus 2021 Versus 2027
2 Hemophilia Drugs Market Competition by Manufacturers
2.1 Global Hemophilia Drugs Sales Market Share by Manufacturers (2016-2021)
2.2 Global Hemophilia Drugs Revenue Market Share by Manufacturers (2016-2021)
2.3 Global Hemophilia Drugs Average Price by Manufacturers (2016-2021)
2.4 Manufacturers Hemophilia Drugs Manufacturing Sites, Area Served, Product Type
2.5 Hemophilia Drugs Market Competitive Situation and Trends
2.5.1 Hemophilia Drugs Market Concentration Rate
2.5.2 The Global Top 5 and Top 10 Largest Hemophilia Drugs Players Market Share by Revenue
2.5.3 Global Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Hemophilia Drugs Retrospective Market Scenario by Region
3.1 Global Hemophilia Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021
3.2 Global Hemophilia Drugs Retrospective Market Scenario in Sales by Region: 2016-2021
3.3 North America Hemophilia Drugs Market Facts & Figures by Country
3.3.1 North America Hemophilia Drugs Sales by Country
3.3.2 North America Hemophilia Drugs Revenue by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Hemophilia Drugs Market Facts & Figures by Country
3.4.1 Europe Hemophilia Drugs Sales by Country
3.4.2 Europe Hemophilia Drugs Revenue by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Hemophilia Drugs Market Facts & Figures by Region
3.5.1 Asia Pacific Hemophilia Drugs Sales by Region
3.5.2 Asia Pacific Hemophilia Drugs Revenue by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Hemophilia Drugs Market Facts & Figures by Country
3.6.1 Latin America Hemophilia Drugs Sales by Country
3.6.2 Latin America Hemophilia Drugs Revenue by Country
3.6.3 Mexico
3.6.4 Brazil
3.6.5 Argentina
3.7 Middle East and Africa Hemophilia Drugs Market Facts & Figures by Country
3.7.1 Middle East and Africa Hemophilia Drugs Sales by Country
3.7.2 Middle East and Africa Hemophilia Drugs Revenue by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Hemophilia Drugs Historic Market Analysis by Type
4.1 Global Hemophilia Drugs Sales Market Share by Type (2016-2021)
4.2 Global Hemophilia Drugs Revenue Market Share by Type (2016-2021)
4.3 Global Hemophilia Drugs Price by Type (2016-2021)
5 Global Hemophilia Drugs Historic Market Analysis by Application
5.1 Global Hemophilia Drugs Sales Market Share by Application (2016-2021)
5.2 Global Hemophilia Drugs Revenue Market Share by Application (2016-2021)
5.3 Global Hemophilia Drugs Price by Application (2016-2021)
6 Key Companies Profiled
6.1 Baxalta
6.1.1 Baxalta Corporation Information
6.1.2 Baxalta Description and Business Overview
6.1.3 Baxalta Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.1.4 Baxalta Product Portfolio
6.1.5 Baxalta Recent Developments/Updates
6.2 Bayer
6.2.1 Bayer Corporation Information
6.2.2 Bayer Description and Business Overview
6.2.3 Bayer Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.2.4 Bayer Product Portfolio
6.2.5 Bayer Recent Developments/Updates
6.3 CSL Behring
6.3.1 CSL Behring Corporation Information
6.3.2 CSL Behring Description and Business Overview
6.3.3 CSL Behring Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.3.4 CSL Behring Product Portfolio
6.3.5 CSL Behring Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Corporation Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Pfizer Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Alnylam Pharmaceuticals
6.5.1 Alnylam Pharmaceuticals Corporation Information
6.5.2 Alnylam Pharmaceuticals Description and Business Overview
6.5.3 Alnylam Pharmaceuticals Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.5.4 Alnylam Pharmaceuticals Product Portfolio
6.5.5 Alnylam Pharmaceuticals Recent Developments/Updates
6.6 BioMarin
6.6.1 BioMarin Corporation Information
6.6.2 BioMarin Description and Business Overview
6.6.3 BioMarin Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.6.4 BioMarin Product Portfolio
6.6.5 BioMarin Recent Developments/Updates
6.7 Catalyst Biosciences
6.6.1 Catalyst Biosciences Corporation Information
6.6.2 Catalyst Biosciences Description and Business Overview
6.6.3 Catalyst Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.4.4 Catalyst Biosciences Product Portfolio
6.7.5 Catalyst Biosciences Recent Developments/Updates
6.8 Dimension Therapeutics
6.8.1 Dimension Therapeutics Corporation Information
6.8.2 Dimension Therapeutics Description and Business Overview
6.8.3 Dimension Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.8.4 Dimension Therapeutics Product Portfolio
6.8.5 Dimension Therapeutics Recent Developments/Updates
6.9 F. Hoffmann-La Roche
6.9.1 F. Hoffmann-La Roche Corporation Information
6.9.2 F. Hoffmann-La Roche Description and Business Overview
6.9.3 F. Hoffmann-La Roche Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.9.4 F. Hoffmann-La Roche Product Portfolio
6.9.5 F. Hoffmann-La Roche Recent Developments/Updates
6.10 Grifols
6.10.1 Grifols Corporation Information
6.10.2 Grifols Description and Business Overview
6.10.3 Grifols Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.10.4 Grifols Product Portfolio
6.10.5 Grifols Recent Developments/Updates
6.11 Octapharma
6.11.1 Octapharma Corporation Information
6.11.2 Octapharma Hemophilia Drugs Description and Business Overview
6.11.3 Octapharma Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.11.4 Octapharma Product Portfolio
6.11.5 Octapharma Recent Developments/Updates
6.12 Sangamo Biosciences
6.12.1 Sangamo Biosciences Corporation Information
6.12.2 Sangamo Biosciences Hemophilia Drugs Description and Business Overview
6.12.3 Sangamo Biosciences Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.12.4 Sangamo Biosciences Product Portfolio
6.12.5 Sangamo Biosciences Recent Developments/Updates
6.13 Spark Therapeutics
6.13.1 Spark Therapeutics Corporation Information
6.13.2 Spark Therapeutics Hemophilia Drugs Description and Business Overview
6.13.3 Spark Therapeutics Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.13.4 Spark Therapeutics Product Portfolio
6.13.5 Spark Therapeutics Recent Developments/Updates
6.14 Swedish Orphan Biovitrum
6.14.1 Swedish Orphan Biovitrum Corporation Information
6.14.2 Swedish Orphan Biovitrum Hemophilia Drugs Description and Business Overview
6.14.3 Swedish Orphan Biovitrum Hemophilia Drugs Sales, Revenue and Gross Margin (2016-2021)
6.14.4 Swedish Orphan Biovitrum Product Portfolio
6.14.5 Swedish Orphan Biovitrum Recent Developments/Updates
7 Hemophilia Drugs Manufacturing Cost Analysis
7.1 Hemophilia Drugs Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Hemophilia Drugs
7.4 Hemophilia Drugs Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Hemophilia Drugs Distributors List
8.3 Hemophilia Drugs Customers
9 Hemophilia Drugs Market Dynamics
9.1 Hemophilia Drugs Industry Trends
9.2 Hemophilia Drugs Growth Drivers
9.3 Hemophilia Drugs Market Challenges
9.4 Hemophilia Drugs Market Restraints
10 Global Market Forecast
10.1 Hemophilia Drugs Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Hemophilia Drugs by Type (2022-2027)
10.1.2 Global Forecasted Revenue of Hemophilia Drugs by Type (2022-2027)
10.2 Hemophilia Drugs Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Hemophilia Drugs by Application (2022-2027)
10.2.2 Global Forecasted Revenue of Hemophilia Drugs by Application (2022-2027)
10.3 Hemophilia Drugs Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Hemophilia Drugs by Region (2022-2027)
10.3.2 Global Forecasted Revenue of Hemophilia Drugs by Region (2022-2027)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Figures, Tables and Charts Available in Global Hemophilia Drugs Market Research Report 2021
List of TablesTable 1. Global Hemophilia Drugs Sales (K MT) Growth Rate Comparison by Type (2021-2027)
Table 2. Global Hemophilia Drugs Sales (K MT) Comparison by Application (2021-2027)
Table 3. Global Hemophilia Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027)
Table 4. Key Manufacturers Hemophilia Drugs Covered in This Study
Table 5. Global Hemophilia Drugs Sales (K MT) of Key Manufacturers (2016-2021)
Table 6. Global Hemophilia Drugs Sales Share by Manufacturers (2016-2021)
Table 7. Global Hemophilia Drugs Revenue (US$ Million) by Manufacturers (2016-2021)
Table 8. Global Hemophilia Drugs Revenue Share by Manufacturers (2016-2021)
Table 9. Global Market Hemophilia Drugs Average Price (USD/MT) of Key Manufacturers (2016-2021)
Table 10. Manufacturers Hemophilia Drugs Manufacturing Sites and Area Served
Table 11. Manufacturers Hemophilia Drugs Product Type
Table 12. Global Hemophilia Drugs Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Hemophilia Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Hemophilia Drugs as of 2020)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Global Hemophilia Drugs Sales by Region (2016-2021) & (K MT)
Table 16. Global Hemophilia Drugs Sales Market Share by Region (2016-2021)
Table 17. Global Hemophilia Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 18. North America Hemophilia Drugs Sales by Country (2016-2021) & (K MT)
Table 19. North America Hemophilia Drugs Sales Market Share by Country (2016-2021)
Table 20. North America Hemophilia Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 21. North America Hemophilia Drugs Revenue Market Share by Country (2016-2021)
Table 22. Europe Hemophilia Drugs Sales by Country (2016-2021) & (K MT)
Table 23. Europe Hemophilia Drugs Sales Market Share by Country (2016-2021)
Table 24. Europe Hemophilia Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 25. Europe Hemophilia Drugs Revenue Market Share by Country (2016-2021)
Table 26. Asia Pacific Hemophilia Drugs Sales by Region (2016-2021) & (K MT)
Table 27. Asia Pacific Hemophilia Drugs Sales Market Share by Region (2016-2021)
Table 28. Asia Pacific Hemophilia Drugs Revenue by Region (2016-2021) & (US$ Million)
Table 29. Asia Pacific Hemophilia Drugs Revenue Market Share by Region (2016-2021)
Table 30. Latin America Hemophilia Drugs Sales by Country (2016-2021) & (K MT)
Table 31. Latin America Hemophilia Drugs Sales Market Share by Country (2016-2021)
Table 32. Latin America Hemophilia Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 33. Latin America Hemophilia Drugs Revenue Market Share by Country (2016-2021)
Table 34. Middle East and Africa Hemophilia Drugs Sales by Country (2016-2021) & (K MT)
Table 35. Middle East and Africa Hemophilia Drugs Sales Market Share by Country (2016-2021)
Table 36. Middle East and Africa Hemophilia Drugs Revenue by Country (2016-2021) & (US$ Million)
Table 37. Middle East and Africa Hemophilia Drugs Revenue Market Share by Country (2016-2021)
Table 38. Global Hemophilia Drugs Sales (K MT) by Type (2016-2021)
Table 39. Global Hemophilia Drugs Sales Market Share by Type (2016-2021)
Table 40. Global Hemophilia Drugs Revenue (Million US$) by Type (2016-2021)
Table 41. Global Hemophilia Drugs Revenue Share by Type (2016-2021)
Table 42. Global Hemophilia Drugs Price (USD/MT) by Type (2016-2021)
Table 43. Global Hemophilia Drugs Sales (K MT) by Application (2016-2021)
Table 44. Global Hemophilia Drugs Sales Market Share by Application (2016-2021)
Table 45. Global Hemophilia Drugs Revenue (Million US$) by Application (2016-2021)
Table 46. Global Hemophilia Drugs Revenue Share by Application (2016-2021)
Table 47. Global Hemophilia Drugs Price (USD/MT) by Application (2016-2021)
Table 48. Baxalta Corporation Information
Table 49. Baxalta Description and Business Overview
Table 50. Baxalta Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 51. Baxalta Hemophilia Drugs Product
Table 52. Baxalta Recent Developments/Updates
Table 53. Bayer Corporation Information
Table 54. Bayer Description and Business Overview
Table 55. Bayer Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 56. Bayer Hemophilia Drugs Product
Table 57. Bayer Recent Developments/Updates
Table 58. CSL Behring Corporation Information
Table 59. CSL Behring Description and Business Overview
Table 60. CSL Behring Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 61. CSL Behring Hemophilia Drugs Product
Table 62. CSL Behring Recent Developments/Updates
Table 63. Pfizer Corporation Information
Table 64. Pfizer Description and Business Overview
Table 65. Pfizer Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 66. Pfizer Hemophilia Drugs Product
Table 67. Pfizer Recent Developments/Updates
Table 68. Alnylam Pharmaceuticals Corporation Information
Table 69. Alnylam Pharmaceuticals Description and Business Overview
Table 70. Alnylam Pharmaceuticals Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 71. Alnylam Pharmaceuticals Hemophilia Drugs Product
Table 72. Alnylam Pharmaceuticals Recent Developments/Updates
Table 73. BioMarin Corporation Information
Table 74. BioMarin Description and Business Overview
Table 75. BioMarin Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 76. BioMarin Hemophilia Drugs Product
Table 77. BioMarin Recent Developments/Updates
Table 78. Catalyst Biosciences Corporation Information
Table 79. Catalyst Biosciences Description and Business Overview
Table 80. Catalyst Biosciences Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 81. Catalyst Biosciences Hemophilia Drugs Product
Table 82. Catalyst Biosciences Recent Developments/Updates
Table 83. Dimension Therapeutics Corporation Information
Table 84. Dimension Therapeutics Description and Business Overview
Table 85. Dimension Therapeutics Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 86. Dimension Therapeutics Hemophilia Drugs Product
Table 87. Dimension Therapeutics Recent Developments/Updates
Table 88. F. Hoffmann-La Roche Corporation Information
Table 89. F. Hoffmann-La Roche Description and Business Overview
Table 90. F. Hoffmann-La Roche Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 91. F. Hoffmann-La Roche Hemophilia Drugs Product
Table 92. F. Hoffmann-La Roche Recent Developments/Updates
Table 93. Grifols Corporation Information
Table 94. Grifols Description and Business Overview
Table 95. Grifols Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 96. Grifols Hemophilia Drugs Product
Table 97. Grifols Recent Developments/Updates
Table 98. Octapharma Corporation Information
Table 99. Octapharma Description and Business Overview
Table 100. Octapharma Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 101. Octapharma Hemophilia Drugs Product
Table 102. Octapharma Recent Developments/Updates
Table 103. Sangamo Biosciences Corporation Information
Table 104. Sangamo Biosciences Description and Business Overview
Table 105. Sangamo Biosciences Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 106. Sangamo Biosciences Hemophilia Drugs Product
Table 107. Sangamo Biosciences Recent Developments/Updates
Table 108. Spark Therapeutics Corporation Information
Table 109. Spark Therapeutics Description and Business Overview
Table 110. Spark Therapeutics Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 111. Spark Therapeutics Hemophilia Drugs Product
Table 112. Spark Therapeutics Recent Developments/Updates
Table 113. Swedish Orphan Biovitrum Corporation Information
Table 114. Swedish Orphan Biovitrum Description and Business Overview
Table 115. Swedish Orphan Biovitrum Hemophilia Drugs Sales (K MT), Revenue (Million US$), Price (USD/MT) and Gross Margin (2016-2021)
Table 116. Swedish Orphan Biovitrum Hemophilia Drugs Product
Table 117. Swedish Orphan Biovitrum Recent Developments/Updates
Table 118. Production Base and Market Concentration Rate of Raw Material
Table 119. Key Suppliers of Raw Materials
Table 120. Hemophilia Drugs Distributors List
Table 121. Hemophilia Drugs Customers List
Table 122. Hemophilia Drugs Market Trends
Table 123. Hemophilia Drugs Growth Drivers
Table 124. Hemophilia Drugs Market Restraints
Table 125. Global Hemophilia Drugs Sales Forecast by Type (2022-2027) & (K MT)
Table 126. Global Hemophilia Drugs Sales Market Share Forecast by Type (2022-2027)
Table 127. Global Hemophilia Drugs Revenue Forecast by Type (2022-2027) & (US$ Million)
Table 128. Global Hemophilia Drugs Revenue Market Share Forecast by Type (2022-2027)
Table 129. Global Hemophilia Drugs Sales Forecast by Application (2022-2027) & (K MT)
Table 130. Global Hemophilia Drugs Sales Market Share Forecast by Application (2022-2027)
Table 131. Global Hemophilia Drugs Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 132. Global Hemophilia Drugs Revenue Market Share Forecast by Application (2022-2027)
Table 133. Global Hemophilia Drugs Sales Forecast by Region (2022-2027) & (K MT)
Table 134. Global Hemophilia Drugs Sales Market Share Forecast by Region (2022-2027)
Table 135. Global Hemophilia Drugs Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 136. Global Hemophilia Drugs Revenue Market Share Forecast by Region (2022-2027)
Table 137. Research Programs/Design for This Report
Table 138. Key Data Information from Secondary Sources
Table 139. Key Data Information from Primary Sources
List of Figures
Figure 1. Product Picture of Hemophilia Drugs
Figure 2. Global Hemophilia Drugs Market Share by Type in 2020 & 2027
Figure 3. Hemophilia A Product Picture
Figure 4. Inhibitors Product Picture
Figure 5. Hemophilia B Product Picture
Figure 6. Von Willebrand Disease Product Picture
Figure 7. Global Hemophilia Drugs Market Share by Application in 2020 & 2027
Figure 8. Recombinant Therapies
Figure 9. Plasma-Derived Therapies
Figure 10. Global Hemophilia Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027
Figure 11. Global Hemophilia Drugs Market Size 2016-2027 (US$ Million)
Figure 12. Global Hemophilia Drugs Sales 2016-2027 (K MT)
Figure 13. Global Hemophilia Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027
Figure 14. Hemophilia Drugs Sales Share by Manufacturers in 2020
Figure 15. Global Hemophilia Drugs Revenue Share by Manufacturers in 2020
Figure 16. The Global 5 and 10 Largest Hemophilia Drugs Players: Market Share by Revenue in 2020
Figure 17. Hemophilia Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021
Figure 18. Global Hemophilia Drugs Sales Market Share by Region (2016-2021)
Figure 19. Global Hemophilia Drugs Sales Market Share by Region in 2020
Figure 20. Global Hemophilia Drugs Revenue Market Share by Region (2016-2021)
Figure 21. Global Hemophilia Drugs Revenue Market Share by Region in 2020
Figure 22. U.S. Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 23. Canada Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 24. Germany Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 25. France Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 26. U.K. Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 27. Italy Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 28. Russia Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 29. China Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 30. Japan Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 31. South Korea Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 32. India Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 33. Australia Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 34. Taiwan Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 35. Indonesia Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 36. Thailand Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 37. Malaysia Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 38. Philippines Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 39. Vietnam Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 40. Mexico Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 41. Brazil Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 42. Argentina Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 43. Turkey Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Saudi Arabia Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 45. U.A.E Hemophilia Drugs Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Sales Market Share of Hemophilia Drugs by Type (2016-2021)
Figure 47. Sales Market Share of Hemophilia Drugs by Application (2016-2021)
Figure 48. Sales Market Share of Hemophilia Drugs by Application in 2020
Figure 49. Revenue Share of Hemophilia Drugs by Application (2016-2021)
Figure 50. Revenue Share of Hemophilia Drugs by Application in 2020
Figure 51. Manufacturing Cost Structure of Hemophilia Drugs
Figure 52. Manufacturing Process Analysis of Hemophilia Drugs
Figure 53. Hemophilia Drugs Industrial Chain Analysis
Figure 54. Channels of Distribution
Figure 55. Distributors Profiles
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Keyplayers in Global Hemophilia Drugs Market Research Report 2021
BaxaltaBayer
CSL Behring
Pfizer
Alnylam Pharmaceuticals
BioMarin
Catalyst Biosciences
Dimension Therapeutics
F. Hoffmann-La Roche
Grifols
Octapharma
Sangamo Biosciences
Spark Therapeutics
Swedish Orphan Biovitrum
Request Sample
Request Discount
